ClinicalTrialsFinder
RecruitingPhase 1NCT07083960

OM336 in Autoimmune Cytopenias

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias

Sponsor

Lakefront Biotherapeutics West LLC

Enrollment

32 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

ITP - Immune ThrombocytopeniaAIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic Anemia

Summary

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called OM336 for people with aiha - cold autoimmune hemolytic anemia, aiha - warm autoimmune hemolytic anemia, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOM336

OM336 is an engineered bispecific antibody directed against BCMA and CD3

Locations(7)

City of Hope

Duarte, California, United States

Medstar

Washington D.C., District of Columbia, United States

University of Michigan

Ann Arbor, Michigan, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

The Canberra Hospital

Canberra, Australian Capital Territory, Australia

Liverpool Hospital

Sydney, New South Wales, Australia

Icon Cancer Center South Brisbane

Brisbane, Queensland, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07083960

Related Trials

Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia

NCT07788456

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT0719485020 locations

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

NCT0754969810 locations

UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia

NCT075303801 location

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

NCT071336591 location